Researchers from Adiso Therapeutics Inc. have reported the discovery of a novel small-molecule dual NLRP1 and NLRP3 inflammasome inhibitor, ADS-032, being developed for the treatment of inflammatory diseases. Screening of an in-house bioactive compound library led to the discovery of ADS-032, a sulfonylurea compound.